[go: up one dir, main page]

WO2019225786A1 - Composition antibactérienne et antifongique comprenant un extrait de clou de girofle, d'hibiscus et de noix de coco comme principe actif - Google Patents

Composition antibactérienne et antifongique comprenant un extrait de clou de girofle, d'hibiscus et de noix de coco comme principe actif Download PDF

Info

Publication number
WO2019225786A1
WO2019225786A1 PCT/KR2018/005962 KR2018005962W WO2019225786A1 WO 2019225786 A1 WO2019225786 A1 WO 2019225786A1 KR 2018005962 W KR2018005962 W KR 2018005962W WO 2019225786 A1 WO2019225786 A1 WO 2019225786A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
hibiscus
composition
clove
antibacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/005962
Other languages
English (en)
Korean (ko)
Inventor
이태후
박설웅
양정은
황은선
박상용
원경화
김슬아
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sd Biotechnologies Co Ltd
Original Assignee
Sd Biotechnologies Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sd Biotechnologies Co Ltd filed Critical Sd Biotechnologies Co Ltd
Publication of WO2019225786A1 publication Critical patent/WO2019225786A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
    • A01N65/08—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
    • A01N65/08—Magnoliopsida [dicotyledons]
    • A01N65/28—Myrtaceae [Myrtle family], e.g. teatree or clove
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
    • A01N65/40—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/577—Malvaceae (Mallow family)
    • A61K36/5775—Hibiscus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/21—Plant extracts
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a composition having antibacterial and antifungal activity, and more particularly to an antibacterial and antifungal composition comprising clove, hibiscus, and coconut extract as an active ingredient.
  • Antimicrobial substances have a selective toxicity that kills microorganisms and are not toxic to humans or animals and are not inactivated by enzymes in the body. This is mainly due to DNA replication, transcription and translation of genetic information, and It inhibits transport, biosynthesis of cell walls, and the like, through the mechanism of inhibiting the growth of microorganisms.
  • the main antimicrobial agents developed to date can be divided into microorganisms, plants, etc., derived from nature and chemically synthesized.
  • the first antimicrobial substance isolated from nature was penicillin, discovered by Alexander Fleming in 1928, and then Many chemically synthesized antimicrobials are used for the treatment of diseases caused by harmful bacteria, but recently, due to increased resistance to chemically synthesized antimicrobial agents, interest in developing antimicrobials using natural antimicrobial agents is increasing. to be.
  • Ginseng extract Patent Application No. 10-1993-0006319
  • Grapefruit Extract Patent Application No. 10-1993-0006320
  • Fennel Conventional Fragrance, Sessin, Camphor and Clove Mixed Extract
  • Green Tea Polyphenol and Tea Tree Oil Patent Application No. 10-2002-0028517
  • Sesbania Grandiprora Extract Patent Application No. 10-2011-0015252
  • the present inventors have diligently sought to find a combination of plant extracts having excellent antibacterial and antifungal activity and at the same time having various functionalities such as skin wrinkle improvement and anti-inflammatory activity, resulting in a combination of clove, hibiscus, and coconut extract. It was confirmed that the extract can be effectively used as an antibacterial and antifungal agent by effectively inhibiting various harmful microorganisms, and completed the present invention.
  • the main object of the present invention is to provide a composition comprising a complex extract of cloves, hibiscus, and coconut as an active ingredient that can effectively inhibit various harmful microorganisms, which can be usefully used as an antibacterial and antifungal agent.
  • the present invention provides an antibacterial and antifungal composition
  • an antibacterial and antifungal composition comprising clove, hibiscus, and coconut extract as an active ingredient.
  • the present inventors searched for a combination of dozens of plant extracts and searched for substances having excellent antibacterial and antifungal efficacy, and found that the combination of cloves, hibiscus, and coconut extract significantly increased the antibacterial and antifungal effect. It was confirmed that there is no problem in safety even when applied to the skin.
  • the term "clove” of the present invention means a plant classified under the scientific name Eugenia caryophyllatum, and the term “Hibiscus syriacus” means a deciduous shrub of the mite family Mallow, which grows throughout the Korean peninsula.
  • cocos Cocos nucifera L.
  • extract is an extract, such as an extract obtained by the extraction process of a plant, a diluent or concentrate of the extract, a dried product obtained by drying the extract, a crude or purified product of the extract, or a mixture thereof. Extracts of all formulations that can be formed using itself and extracts.
  • the extract of the present invention may be preferably prepared and used in the form of a dry powder after extraction.
  • the clove, hibiscus, and coconut extract of the present invention can be extracted from natural, hybrid or variety plants, can also be extracted from plant tissue culture, extracts extracted from the leaves, stems, roots, flowers, fruit, etc. It includes.
  • the clove, hibiscus, and coconut are most preferably combined in a weight ratio of 1: 8: 9.
  • the clove, hibiscus, and coconut were mixed in various ratios to prepare an antimicrobial and antifungal composition, and to confirm the antimicrobial activity of the prepared composition, agar diffusion (disc diffusion test) and microbial growth inhibition concentration evaluation was performed.
  • agar diffusion test disc diffusion test
  • microbial growth inhibition concentration evaluation was performed.
  • the combination of clove, hibiscus, and coconut showed an excellent antimicrobial activity as a whole, especially when compared to the methylparaben and grapefruit seed extract used as a control group, showed the same or more antibacterial effect, the clove, hibiscus, and coconut
  • the composition mixed with the extract in a ratio of 1: 8: 9 has the best synergistic effect.
  • the antimicrobial and antifungal compositions of the present invention have a broad antimicrobial spectrum, specifically, antimicrobial activity against Gram-positive bacteria, Gram-negative bacteria, yeast, and fungi.
  • the composition of the present invention has antifungal activity against Candida fungi and Aspergillus fungi, and more specifically, antifungal activity against Candida albicans and Aspergillus niger.
  • the present invention is not limited thereto.
  • composition of the present invention has antimicrobial activity specifically against Escherichia sp. Strains, and Gram-negative strains of Pseudomonas sp., More specifically Escherichia coli, and Pseudomonas aeruginosa. There is antibacterial activity against Pseudomonas aeruginosa strains, but is not limited thereto.
  • composition of the present invention has an antimicrobial activity against Bacillus sp. Strain, and Gram-positive strain of Staphylococcus spp., More specifically Staphylococcus aureus, Bacillus sub Antibacterial activity against bacteria such as Bacillus subtilis, but is not limited thereto.
  • the antibacterial effect of the clove, hibiscus, and coconut complex extract was assayed. As a result, it was confirmed that the combination thereof had a very good antimicrobial activity compared to each single compound.
  • collagen of dermal fibroblasts can be said to be directly related to the repair or regeneration of tissue during skin regeneration, skin elasticity, skin wrinkle formation and skin damage.
  • 'MMP' matrix metallo-proteinase
  • Clove, hibiscus, and coconut complex extract of the present invention is characterized by inhibiting the expression of MMP-1 protein.
  • the composition comprising the extract of the clove, hibiscus, and coconut complex of the present invention as an active ingredient is a substrate protease-1 which reduces cytotoxicity and promotes collagen degradation in normal human dermal fibroblasts (NHDF) irradiated with ultraviolet rays.
  • NHDF normal human dermal fibroblasts
  • inhibits the expression of matrix metallo-proteinases such as increased skin elasticity, skin regeneration, skin wrinkle improvement, wound healing, repair and regeneration of damaged skin tissue; And it can have effects, such as anti-aging of skin. Specifically, it may have an effect of preventing or improving skin wrinkles (see FIG. 1).
  • composition of the clove, hibiscus, and coconut complex extract of the present invention as an active ingredient is characterized by inhibiting the expression of IL-6 protein (see Fig. 2). Damaged skin is further enlarged through inflammatory reactions, and skin tends to be worsened clinically through skin redness, skin hypersensitivity, or photosensitization. Therefore, early blocking of inflammatory response is very important for effective improvement of damaged skin condition.
  • the treatment of the clove, hibiscus, and coconut complex extract has been shown to inhibit the production of IL-6 protein, an inflammation mediator, and the inhibitory ability of the IL-6 protein expression is concentration dependent. Appeared to be. Therefore, the composition of the present invention effectively inhibits the production of the IL-6 protein, an inflammation mediator, and effectively blocks the inflammatory response around the skin, thereby effectively acting to improve the condition of the damaged skin.
  • the complex extract of the clove, hibiscus, and coconut of the present invention shows an excellent antioxidant effect, this antioxidant effect was found to be superior when compared to the arbutin positive control group (see Figure 3).
  • the present invention provides a pharmaceutical composition for antibacterial and antifungal comprising the clove, hibiscus, and coconut extract as an active ingredient.
  • the complex plant extract of clove, hibiscus, and coconut of the present invention exhibits excellent antibacterial and antifungal activity through direct effects on harmful microorganisms, and thus can be usefully used as a pharmaceutical composition for antibacterial and antifungal diseases.
  • antimicrobial and antifungal compositions comprising clove, hibiscus, and coconut extract of the present invention as an active ingredient may be prepared in the form of a pharmaceutically acceptable salt.
  • salts can be formed by the addition of acids, for example inorganic acids (e.g. hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, etc.), organic carboxylic acids (e.g.
  • acetic acid, trifluoroacetic acid Acetic acid, propionic acid, maleic acid, succinic acid, malic acid, citric acid, tartaric acid, salicylic acid), and acidic sugars (glucuronic acid, galacturonic acid, gluconic acid, ascorbic acid), acidic polysaccharides (e.g. hyaluronic acid, chondroitin sulfate, Salts can be formed by addition of organic sulfonic acids (eg, methane, sulfonic acid, p-toluene sulfonic acid), including sulfonic acid sugar esters such as arginine acid), chondroitin sulfate.
  • organic sulfonic acids eg, methane, sulfonic acid, p-toluene sulfonic acid
  • sulfonic acid sugar esters such as arginine acid
  • Antimicrobial and antifungal compositions comprising clove, hibiscus, and coconut extract of the present invention as active ingredients can be administered orally or parenterally during clinical administration with natural plant extracts and can be used in the form of general pharmaceutical formulations.
  • the antimicrobial and antifungal composition comprising the clove, hibiscus, and coconut extract of the present invention as an active ingredient may be administered in various oral or parenteral formulations, and when formulated, commonly used fillers, extenders, and binders. And diluents or excipients such as wetting agents, disintegrating agents and surfactants.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • base of the suppository witepsol, macrogol, tween 61, cacao butter, uririnji, glycerogelatin and the like can be used.
  • the antimicrobial and antifungal composition comprising the clove, hibiscus, and coconut extract of the present invention as an active ingredient can be used in combination with various carriers (pharmaceutically acceptable carrier) such as physiological saline or organic solvent, stability or absorbency Carbohydrates such as glucose, sucrose or dextran, antioxidants such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other stabilizers are used to increase Can be used as
  • the effective dose of the antimicrobial and antifungal composition comprising clove, hibiscus, and coconut extract of the present invention as an active ingredient is 0.01 to 10 mg / kg, preferably 0.1 to 1 mg / kg, once to three times a day. May be administered.
  • the total effective amount may be administered to the patient in a single dose by bolus form or by infusion for a relatively short period of time, and the like. Multiple does may be administered by a fractionated treatment protocol with long term administration. Since the concentration is determined by taking into consideration various factors such as the age and health condition of the patient as well as the route of administration and the number of treatments of the drug, in view of the above, the present invention is a person having ordinary skill in the art. Appropriate effective dosages for the specific use of the clove, hibiscus, and coconut complex plant extract as pharmaceutical compositions may be determined.
  • the present invention provides a cosmetic composition for antibacterial and antifungal comprising clove, hibiscus, and coconut extract as an active ingredient.
  • the antimicrobial and antifungal cosmetic composition comprising the clove, hibiscus, and coconut extract of the present invention as an active ingredient is extracted from natural plant material, which is harmless to the human body, and effectively prevents the cosmetic from being corrupted by harmful microorganisms, Since the addition does not impair the quality of the material of the cosmetic, it is suitable to be used in the cosmetic composition, and particularly, it is preferable to be used in the cosmetic composition because it has skin improvement, skin inflammation relief, and antioxidant effect.
  • the content of the antimicrobial and antifungal cosmetic composition may be contained in 0.001 to 10% by weight.
  • the cosmetic composition of the present invention contains ingredients commonly used in cosmetic compositions in addition to the cloves, hibiscus, and coconut extract as an active ingredient, and for example, conventional adjuvants such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavorings. And carriers.
  • Cosmetic compositions of the present invention may be prepared in any formulation conventionally prepared in the art and include, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing , Oils, powder foundations, emulsion foundations, wax foundations and sprays, and the like, but are not limited thereto. More specifically, it may be prepared in the form of a flexible lotion (skin), nutrition lotion (milk lotion), nutrition cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder .
  • the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanta, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide are used as carrier components.
  • animal oil, vegetable oil, wax, paraffin, starch, tragacanta, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide are used as carrier components.
  • tragacanta cellulose derivative
  • polyethylene glycol silicone
  • bentonite silica
  • talc talc
  • zinc oxide zinc oxide
  • lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular in the case of a spray, additionally chlorofluorohydrocarbon, propane Propellant such as butane or dimethyl ether.
  • a solvent, solubilizer or emulsifier is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
  • liquid carrier diluents such as water, ethanol or propylene glycol
  • suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, microcrystals Soluble cellulose, aluminum metahydroxy, bentonite, agar or tragacanta and the like can be used.
  • the carrier component is aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide.
  • Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
  • cosmetics of the present invention include a female cleanser, hand cleanser, cleansing cream, cleansing foam, cleansing cream, cleansing milk, cleansing lotion, massage cream, cold cream, moisturizing cream, latex, lotion, pack, aftershave cream, sunscreen , Suntan oil, soap, body shampoo, hair shampoo, hair rinse, hair treatment, wool, hair restorer, hair cream, hair liquid, set lotion, hair spray, hair bridge, coloring, color spray, permanent wave liquid , Press powder, loose powder, eye shadow, hand cream, lipstick, and the like.
  • the present invention provides a food composition or feed preservation composition for antibacterial and antifungal, comprising clove, hibiscus, and coconut extract as an active ingredient.
  • Food and feed preservatives are additives used to prevent the deterioration, decay, discoloration and chemical change of food or feed, including fungicides and antioxidants, and inhibit the growth of microorganisms such as bacteria, fungi and yeasts.
  • Functional antibacterial agents such as inhibiting the development or sterilization of decaying microorganisms in cosmetics, cosmetics, pharmaceuticals, and the like are included.
  • Ideal conditions for preservatives of these foods or feeds should be nontoxic and effective in trace amounts.
  • the antimicrobial and antifungal food composition or feed preservation composition comprising clove, hibiscus, and coconut extract of the present invention as an active ingredient exhibits excellent antimicrobial and antifungal activity through direct influence on harmful microorganisms. It can be widely used for preservatives, cosmetic preservatives and pharmaceutical preservatives.
  • the present invention comprises the step of killing pathogenic bacteria by administering to the subject in need of the antimicrobial and antifungal composition comprising the clove, hibiscus, and coconut extract as an active ingredient, Provided are methods for treating bacterial or fungal infectious diseases in animals other than humans.
  • the method for treating bacterial or fungal infectious diseases of animals other than humans does not mean that the method of treating animals except humans is not effective in humans.
  • the symptoms of which can be improved by administration of the therapeutic composition according to the present invention can be sufficiently used in the treatment of humans.
  • the term "animal other than human” refers to horses, sheep, pigs and goats, except for humans having diseases caused by infection of bacteria or fungi whose symptoms may be improved by administration of the therapeutic composition according to the present invention.
  • Means animals such as camels, antelopes and dogs.
  • administration means introducing a predetermined substance into the animal by any suitable method, and the route of administration of the therapeutic composition according to the present invention is oral or via any general route as long as it can reach the target tissue. Parenteral administration.
  • the therapeutic composition according to the present invention can be administered by any device that the active ingredient can move to the target cell.
  • Preferred dosages for the therapeutic compositions according to the invention vary depending on the condition and weight of the animal to be treated, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art.
  • the pharmaceutical composition of the present invention is 0.01 to 10 mg / kg, preferably 0.1 to 1 mg / kg, and may be administered once to three times a day.
  • composition of the present invention has an antibacterial and antifungal effect on its own, it can be directly used as an antibacterial and antifungal composition, and can be used in the form of mixing with other ingredients containing natural extracts having antibacterial and antifungal effects. It is expected that the antimicrobial or antifungal effect can be enhanced.
  • the present invention provides an antimicrobial and antifungal composition
  • clove, hibiscus, and coconut extract as an active ingredient.
  • the antimicrobial and antifungal composition comprising the clove, hibiscus, and coconut extract of the present invention as an active ingredient exhibits a broad antimicrobial and antifungal spectrum against various bacteria, while inhibiting the expression of MMP-1 in human dermal fibroblasts. Inhibits the occurrence of skin wrinkles, and improves the inflammatory response of damaged skin.
  • composition of the present invention can also be usefully used for antibacterial, antifungal and antiseptic purposes in various fields such as cosmetic compositions, food or feed preservative additive compositions.
  • 1 is a graph showing the inhibitory effect of MMP-1 expression of the complex extract of clove, hibiscus, and coconut of the present invention.
  • Figure 2 is a graph showing the IL-6 inhibitory effect of the complex extract of clove, hibiscus, and coconut of the present invention.
  • Figure 3 is a graph showing the antioxidant effect of the complex extract of clove, hibiscus, and coconut of the present invention.
  • the dried cloves weighing 100 g of dry weight, were refluxed for 12 hours with a 70% (V / V) ethanol aqueous solution, cooled, and then filtered through a filter paper (Glassfiber, sartorius, USA) having a permeation size of 1.2 ⁇ m.
  • the filtered extract was concentrated under reduced pressure at 50 ° C. or lower and completely dried using a reduced pressure dryer (Eyela Rotary evaporator, Tokyo Rikakika Co., Ltd., Japan) to obtain 12 g of clove extract.
  • the dried hibiscus with a dry weight of 100 g was heated and refluxed for 12 hours with an aqueous 70% (V / V) ethanol solution, cooled and then filtered through a filter paper (Glassfiber, sartorius, USA) having a permeation size of 1.2 ⁇ m.
  • the filtered extract was concentrated under reduced pressure at 50 ° C. or lower and completely dried using a reduced pressure dryer (Eyela Rotary evaporator, Tokyo Rikakika Co., Ltd., Japan) to obtain 31 g of a hibiscus extract.
  • E. coli KCTC2571 Pseudomonas aeruginosa KCTC2513, Staphylococcus aureus KCTC3881 and Bacillus subtilis KCTC1021, and the fungus albicans albicans KCTC7965) and Aspergillus niger (Aspergillus niger KCTC6317) were used (KCTC Bioresource Center, Korea Research Institute of Bioscience and Biotechnology).
  • Each strain prepared the Nutrient Broth solution of Table 1 and sterilized at 121 ° C. for 15 minutes, and then inoculated each cultured Strain 1 platinum into a nutrient solution (10 ml), and shaking incubator. incubator for 24 hours to prepare a strain for the antimicrobial experiment.
  • bacteria of the strains cultured in a sterile culture medium is 1 X 10 6 cfu / ml, fungi, each at a concentration of 1 X 10 5 cfu / ml Inoculation.
  • Three single extracts prepared in Example 1 were dissolved in ethanol at a concentration of 2%, dropped twice at 25 ⁇ l on sterile paper discs (diameter 8 mm) and dried sufficiently. After the extract is completely dried, it is placed on a plate medium and maintained at 28-37 ° C. After 1, 2 and 3 days (observe up to 7 days for A. niger), the clear zone around the paper disc is measured. The antimicrobial activity was examined (Test Example 1 Clove Extract, Test Example 2: Hibiscus Extract, Test Example 3: Coconut Extract).
  • the clove extract (Test Example 1) was found to have a similar degree of antimicrobial activity compared to the grapefruit seed extract (Comparative Example 2), but Hibiscus (Test Example 2) or coconut extract (Test Example 3) Compared with silver methyl paraben (comparative example 1), it was observed that it has antimicrobial activity of comparative inferiority.
  • MIC microbial growth minimum inhibitory concentration
  • MIC measurement was obtained by incubating each bacteria and fungi in a solid agar medium, 5 colonies were obtained according to 1 ⁇ 10 5-6 CFU / mL, diluted in the medium and inoculated and maintained at 37 ° C. for 2-3 hours.
  • Plant extracts used in this experiment were titrated at a concentration of 2.0mg / mL and diluted in 2-fold series. Transfer the medium containing each bacterium and compound to a 96 well plate and incubate at 37 ° C. for 16-24 hours, and measure the minimum inhibitory concentration of single extracts by measuring it at 600 nm using the Multilabel Counter (1420, Perkin Elmer). It is shown in [Table 3].
  • MIC microbial growth inhibitory concentration
  • checkboard assay which is a method for identifying the antimicrobial synergy by combining antimicrobial substances.
  • the antimicrobial activity was set to 6 rows x 6 columns, and the clove and hibiscus extracts, which were used to measure the mixing effect on 96 well plates, were diluted two-fold at MIC concentrations, and the clove extracts were horizontal and the hibiscus extracts were vertical. Diluted with. After incubating for 16-24 hours at 37 °C, it was defined as the lowest mutually inhibited concentration of the complex extract, the interaction between the two compounds is represented by the FIC (fractional inhibitory concentration) of the following [Equation 1] It was.
  • FICI FICI index
  • composition of the clove extract and hibiscus extract in a ratio of 1: 8 has a synergistic or added antimicrobial and antifungal effect on all harmful microorganisms, and referring to the comparison table of the following [Table 10], The composition of the clove extract and hibiscus extract in a ratio of 1: 8 showed an antimicrobial activity similar to that of the methylparaben or grapefruit seed extract of the comparative example, it was confirmed that the most synergistic effect.
  • the microbial growth minimum inhibition concentration (MIC) was measured according to the ratio of these complex extracts.
  • the experiment was evaluated in the same manner as in Example 3-3 while fixing the mixing ratio (1: 8) of the clove and hibiscus best antibacterial and antifungal effect, and mixed with the coconut extract, the measurement results [ Table 11 summarized.
  • composition in which the complex extract of clove and hibiscus (1: 8) and the coconut extract were mixed at a ratio of 1: 1 has an antibacterial and antifungal effect on all harmful microorganisms.
  • the composite extract of clove, hibiscus, and coconut extract in a ratio of 1: 8: 9 is 97.6% -99.3% of the average value of each single extract, 50 of the two complex extracts of clove and hibiscus of Test Example 4 % -75% reduced harmful microbial growth minimum concentration was measured, it was confirmed that the best synergistic effect.
  • NHDFs normal human dermal fibroblasts
  • normal human dermal fibroblasts were seeded in 40 mm tissue culture plates (1.2 ⁇ 10 5 cells). When normal human dermal fibroblasts reached 80% fusion, they were washed twice with phosphate buffered saline (PBS) and 1980 ⁇ l of fresh serum-free medium and 20 ⁇ l of sample were added to each well and then normal human dermis Fibroblasts were washed three times with warm PBS.
  • PBS phosphate buffered saline
  • MMP-1 matrix metalloproteinase activity was evaluated in supernatants taken 72 hours after UVB irradiation. Supernatants collected using an ELISA reader were measured at 450 nm.
  • HaCaT cells The cells were plated in 100 mm tissue culture plates, with a humid environment containing 5% CO 2 , 10% heat-inactivated FBS and 1% penicillin-streptomycin at 37 ° C. Cultured in supplemented DMEM medium.
  • HaCaT cells Normal human epidermal keratinocytes (HaCaT cells) were seeded in 40 mm tissue culture plates (1.0 ⁇ 10 5 cells). When normal human dermal fibroblasts reached 80% fusion, they were washed twice with phosphate buffered saline (PBS), 1980 ⁇ l of fresh serum-free medium and 20 ⁇ l of sample were added to each well, and then HaCaT cells Wash three times with warm PBS.
  • PBS phosphate buffered saline
  • IL-6 protein was evaluated in supernatants taken 24 hours after UVB irradiation. Supernatants collected using an ELISA reader were measured at 450 nm.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Animal Husbandry (AREA)
  • Nutrition Science (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition antibactérienne et antifongique comprenant un extrait de clou de girofle, d'hibiscus et de noix de coco comme principe actif. L'extrait combiné de clou de girofle, d'hibiscus et de de noix de coco selon la présente invention présente une excellente activité antibactérienne et antifongique en exerçant une influence directe sur des microbes nocifs tout en ayant des effets, tels que la réduction des rides de la peau, le soulagement de l'inflammation dermique, l'antioxydation, etc. Ainsi, l'extrait peut être avantageusement utilisé dans une composition pharmaceutique, une composition cosmétique, un conservateur pour conserver des aliments ou des aliments pour animaux, etc.
PCT/KR2018/005962 2018-05-23 2018-05-25 Composition antibactérienne et antifongique comprenant un extrait de clou de girofle, d'hibiscus et de noix de coco comme principe actif Ceased WO2019225786A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180058651A KR102059392B1 (ko) 2018-05-23 2018-05-23 정향, 히비스커스, 및 코코넛 추출물을 유효성분으로 포함하는 항균 및 항진균 조성물
KR10-2018-0058651 2018-05-23

Publications (1)

Publication Number Publication Date
WO2019225786A1 true WO2019225786A1 (fr) 2019-11-28

Family

ID=68615874

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/005962 Ceased WO2019225786A1 (fr) 2018-05-23 2018-05-25 Composition antibactérienne et antifongique comprenant un extrait de clou de girofle, d'hibiscus et de noix de coco comme principe actif

Country Status (2)

Country Link
KR (1) KR102059392B1 (fr)
WO (1) WO2019225786A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115089538A (zh) * 2022-07-26 2022-09-23 吴流俊 一种以皂角米为主要配方的洗发水

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102386077B1 (ko) * 2020-03-13 2022-04-12 주식회사 케이티앤지 장구채 추출물을 유효성분으로 포함하는 항균 조성물
KR102776756B1 (ko) 2022-07-27 2025-03-07 그린코스 주식회사 두켜부채, 해당화 및 여뀌 혼합 추출물을 이용한 항균활성 및 항균효과를 보이는 피부 개선용 화장료 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100099547A (ko) * 2009-03-03 2010-09-13 (주)지원메디코스 아토피 피부 개선을 위한 클린징 화장료 조성물 및 그 제조방법
KR20140042847A (ko) * 2011-06-30 2014-04-07 다카사고 고료 고교 가부시키가이샤 항균 조성물
US20150250224A1 (en) * 2012-06-04 2015-09-10 Universidad Autonoma Del Estado De Hildago Phytochemical compositions used as disinfectants and preservatives for food
CN105326680A (zh) * 2015-10-31 2016-02-17 夏子煜 一种儿童洗手液
KR20180017952A (ko) * 2016-08-11 2018-02-21 (주)에스디생명공학 식물 복합 추출물을 유효성분으로 함유하는 천연 방부제 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100099547A (ko) * 2009-03-03 2010-09-13 (주)지원메디코스 아토피 피부 개선을 위한 클린징 화장료 조성물 및 그 제조방법
KR20140042847A (ko) * 2011-06-30 2014-04-07 다카사고 고료 고교 가부시키가이샤 항균 조성물
US20150250224A1 (en) * 2012-06-04 2015-09-10 Universidad Autonoma Del Estado De Hildago Phytochemical compositions used as disinfectants and preservatives for food
CN105326680A (zh) * 2015-10-31 2016-02-17 夏子煜 一种儿童洗手液
KR20180017952A (ko) * 2016-08-11 2018-02-21 (주)에스디생명공학 식물 복합 추출물을 유효성분으로 함유하는 천연 방부제 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHILLING, M. ET AL.: "Antimicrobial Effects of Virgin Coconut Oil and Its Medium-Chain Fatty Acids on Clostridium difficile", JOURNAL OF MEDICINAL FOOD, vol. 16, no. 12, 2013, pages 1079 - 1085, XP055598345, DOI: 10.1089/jmf.2012.0303 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115089538A (zh) * 2022-07-26 2022-09-23 吴流俊 一种以皂角米为主要配方的洗发水

Also Published As

Publication number Publication date
KR20190133562A (ko) 2019-12-03
KR102059392B1 (ko) 2019-12-26

Similar Documents

Publication Publication Date Title
KR101864409B1 (ko) 한방 추출물 및 미생물 발효추출물을 유효성분으로 함유하는 항균, 살균 또는 항진균용 조성물
WO2019225785A1 (fr) Composition antimicrobienne et antifongique comprenant de l'eugénol et de l'acide gallique en tant que principes actifs
KR102065185B1 (ko) 항균, 항염, 피부주름 개선, 및 피부 미백 활성을 갖는 피부상태 개선용 조성물
KR101483749B1 (ko) 비타민나무 추출물을 포함하는 미백용 화장료 조성물 및 항균제 조성물
KR100973221B1 (ko) 판두라틴 에이 또는 그의 유도체의 신규한 용도
KR101333150B1 (ko) 식물 추출물 또는 이의 분획물에 대한 빛 조사물을 포함하는 항균용 조성물
KR102059392B1 (ko) 정향, 히비스커스, 및 코코넛 추출물을 유효성분으로 포함하는 항균 및 항진균 조성물
CN112220891A (zh) 含有草本混合精油作为有效成分的抗菌及抗真菌组合物
KR100699333B1 (ko) 복분자 또는 산딸기의 뿌리 추출물을 함유하는 항균용 조성물
WO2023113399A1 (fr) Composition cosmétique fonctionnelle antibactérienne pour anti-oxydation, anti-inflammation et anti-âge comprenant un extrait de fleur de gardenia florida, un extrait de pelargonium graveolens, et un extrait de salvia officinalis comme principes actifs
KR101928211B1 (ko) 수족구 원인균 엔테로바이러스 71을 포함한 바이러스 및 균에 대해 저해 효과를 갖는 조성물
KR101392808B1 (ko) 식물 추출물 또는 이의 분획물을 포함하는 항균용 조성물
EP2512495B1 (fr) Procede pour obtenir un extrait standardise de quercetine et de 3-o-methylquercetine a partir d'inflorescences de macela-do-campo, et composition cosmetique, pharmaceutique et veterinaire le contenant
KR20130112322A (ko) 슈퍼박테리아에 대한 항균 활성 및 항염증 활성을 나타내는 냉이 추출물을 유효성분으로 포함하는 조성물
KR20240004199A (ko) 올벚나무 추출물, 이의 분획물을 포함하는 항균용 조성물
KR102367027B1 (ko) 등수국 추출물 또는 이의 분획물을 유효성분으로 함유하는 항균용 조성물
KR20210048021A (ko) 당귤껍질 추출물, 후박 추출물 및 폴리리신을 포함하는 항균용 조성물
KR100562077B1 (ko) 피부보호, 피부 트러블 방지, 피부 유해균 성장억제, 여드름 예방 및 항균특성을 가지는 석류피 추출물의 제조방법 및 그 제조방법으로부터 제조된 석류피 추출물을 함유하는 피부외용 항균조성물
KR102507175B1 (ko) 세이지 추출물, 소목 추출물, 어성초 추출물, 로즈마리 추출물, 마늘 추출물, 및 황련 추출물을 유효성분으로 포함하는 항균용 화장료 조성물
US8574556B2 (en) Antibacterial pharmaceutical composition comprising Aceriphyllum rossii extract and active compounds isolated therefrom
KR102488864B1 (ko) 가자 추출물 및 애엽 추출물을 함유하는 피부세균총의 생장 조절 또는 피부 면역 강화용 조성물
KR100787634B1 (ko) 방부 활성을 가지는 화장료 조성물
KR102818229B1 (ko) 락토바실러스 균주를 이용한 강활 및 자초 추출물의 발효물을 유효성분으로 포함하는 항균 조성물
KR20140099223A (ko) 식물 추출물을 이용한 항균 조성물
KR102486044B1 (ko) 천연물 유래 항균 및 항바이러스 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18919564

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, EPO FORM 1205A DATED 21.04.2021

122 Ep: pct application non-entry in european phase

Ref document number: 18919564

Country of ref document: EP

Kind code of ref document: A1